期刊
MOLECULAR PHARMACEUTICS
卷 14, 期 10, 页码 3464-3472出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.7b00477
关键词
biophysical inhibition; lung surfactant; PEGylation; poloxamer; polymer nanoparticles
资金
- Deutsche Forschungsgemeinschaft [BE 5308/1-1, RU 1866/1-2]
- Wirtschafts- und Infrastrukturbank Hessen (Nanosurfact)
- Danish Council for Independent Research [DFF-12-131927]
Lung-delivered polymer nanoparticles provoked dysfunction of the essential lung surfactant system. A steric shielding of the nanoparticle surface with poloxamers could minimize the unwanted interference of polymer nanoparticles with the biophysical function of lung surfactant. The extent of poly(styrene) and poly(lactide) nanoparticle-induced lung surfactant inhibition could be related to the type and content of the applied poloxamer. Escalations of the adsorbed coating layer thickness (> 3 nm) as well as concentration (brush- rather than mushroom-like conformation of poly(ethylene glycol), chain-to-chain distance of < 5 nm) on the colloidal surface were capable of circumventing bioadverse effects. Accordingly, specific formulations (i.e., poloxamer 188, 338, and 407) avoided a perturbation of the microstructure and surface activity of Alveofact and a depletion of the content of surfactant-associated proteins. Poloxamer-modified polymer nanoparticles represent a promising nanomedicine platform intended for respiratory delivery revealing negligible effects on the biophysical functionality of the lining layer present in the deep lungs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据